CN103562406B - 用于预测对艾日布林的反应的方法和组合物 - Google Patents

用于预测对艾日布林的反应的方法和组合物 Download PDF

Info

Publication number
CN103562406B
CN103562406B CN201280013701.8A CN201280013701A CN103562406B CN 103562406 B CN103562406 B CN 103562406B CN 201280013701 A CN201280013701 A CN 201280013701A CN 103562406 B CN103562406 B CN 103562406B
Authority
CN
China
Prior art keywords
eribulin
subject
expression level
tubb6
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280013701.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103562406A (zh
Inventor
S·I·阿古尔尼克
M·C·伯恩
B·A·利特菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN103562406A publication Critical patent/CN103562406A/zh
Application granted granted Critical
Publication of CN103562406B publication Critical patent/CN103562406B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
CN201280013701.8A 2011-03-18 2012-03-16 用于预测对艾日布林的反应的方法和组合物 Expired - Fee Related CN103562406B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161454426P 2011-03-18 2011-03-18
US61/454,426 2011-03-18
PCT/US2012/029479 WO2012129100A1 (en) 2011-03-18 2012-03-16 Methods and compositions for predicting response to eribulin

Publications (2)

Publication Number Publication Date
CN103562406A CN103562406A (zh) 2014-02-05
CN103562406B true CN103562406B (zh) 2018-03-27

Family

ID=45879070

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280013701.8A Expired - Fee Related CN103562406B (zh) 2011-03-18 2012-03-16 用于预测对艾日布林的反应的方法和组合物

Country Status (8)

Country Link
US (1) US9637795B2 (enExample)
EP (1) EP2686441B1 (enExample)
JP (3) JP2014509515A (enExample)
CN (1) CN103562406B (enExample)
CA (1) CA2828959A1 (enExample)
ES (1) ES2731653T3 (enExample)
SG (2) SG193489A1 (enExample)
WO (1) WO2012129100A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101495951B1 (ko) 2009-03-30 2015-02-25 에자이 알앤드디 매니지먼트 가부시키가이샤 리포솜 조성물
RU2689977C2 (ru) * 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
KR102265952B1 (ko) * 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
KR20170039096A (ko) * 2014-05-28 2017-04-10 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료에 있어서 에리불린의 용도
AU2016226157B2 (en) * 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
EP4053278A1 (en) * 2015-05-01 2022-09-07 Japan Science and Technology Agency Anti-tumor agent suppressing or inhibiting zic5
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2020179712A1 (en) * 2019-03-01 2020-09-10 Eisai R&D Management Co., Ltd. Methods for predicting tumor response to eribulin
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN113174427B (zh) * 2021-04-29 2023-02-28 遵义医科大学 基于DNA分子检测ERGIC3 mRNA的方法
CN113512733B (zh) * 2021-05-13 2022-07-26 浙江工业大学 一种电化学nhk反应合成艾日布林中间体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032347A2 (en) * 2003-10-01 2005-04-14 The Ohio State University Research Foundation Determining the chemosensitivity of cells to cytotoxic agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
IL139960A0 (en) 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
WO2006076100A2 (en) * 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
TW201132813A (en) * 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032347A2 (en) * 2003-10-01 2005-04-14 The Ohio State University Research Foundation Determining the chemosensitivity of cells to cytotoxic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eribulin mesylate for the treatment of breast cancer;Cigler T et al.;《Expert opinion on pharmacotherapy》;20100601;第11卷(第9期);第1591页,右栏第3段 *
Salivary Transcriptomic Biomarkers for detection of resectable Pancreatic cancer;Zhang L et al.;《Gastroenterology》;20100301;第138卷(第3期);摘要 *

Also Published As

Publication number Publication date
JP2014509515A (ja) 2014-04-21
JP2017148049A (ja) 2017-08-31
US9637795B2 (en) 2017-05-02
JP2019150027A (ja) 2019-09-12
WO2012129100A1 (en) 2012-09-27
SG10201602147YA (en) 2016-05-30
EP2686441B1 (en) 2019-05-08
ES2731653T3 (es) 2019-11-18
CA2828959A1 (en) 2012-09-27
EP2686441A1 (en) 2014-01-22
US20140235707A1 (en) 2014-08-21
JP6612280B2 (ja) 2019-11-27
SG193489A1 (en) 2013-10-30
CN103562406A (zh) 2014-02-05

Similar Documents

Publication Publication Date Title
CN103562406B (zh) 用于预测对艾日布林的反应的方法和组合物
EP3458604B1 (en) Method for determining sensitivity to a cdk4/6 inhibitor
US7932031B2 (en) Methods for determining sensitivity to microtubule-stabilizing agents comprising ixabepilone by measuring the level of estrogen receptor 1
US20090275608A1 (en) Methods of diagnosing and treating parp-mediated diseases
CA2844793A1 (en) Methods and compositions for the treatment and diagnosis of cancer
US20130143753A1 (en) Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
KR20140047664A (ko) 암에 걸린 대상자에 있어서 화학요법에 대한 임상반응의 예측 방법
JP2023500950A (ja) マントル細胞リンパ腫（ｍｃｌ）対象を特定するための鉄スコアおよびインビトロ方法ならびに治療的使用および方法
WO2020082037A1 (en) Methods for treating a subtype of small cell lung cancer
JPWO2016148115A1 (ja) ホスファチジルセリンシンターゼ１阻害剤への応答性を予測する方法
KR102238258B1 (ko) 간암 진단을 위한 신규 바이오마커 및 이를 이용한 치료 방법
US10881677B2 (en) Composition for modulating IRAK1
TWI595879B (zh) Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity
EP3696545A1 (en) Method for predicting the resistance of melanoma to a treatment with a braf inhibitor
KR20200089595A (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
US20240102105A1 (en) Biomarker for predicting responsiveness to anticancer agent and use thereof
CN111910005A (zh) Cdk4/6抑制剂敏感性相关基因及其应用
US20250002918A1 (en) Compositions and methods for treatment of mic60 depleted cancers and metastasis
JP6478417B2 (ja) 大腸癌患者の生存を予測及び改善するための方法
JP2025524379A (ja) 膵臓がんにおけるバイオマーカー
WO2024227553A1 (en) Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
JP2010200625A (ja) 食道がんに対する放射線化学療法感受性マーカー
EP3231875A1 (en) Prognostic biomarker for cancer
CN103620412A (zh) 作为对表皮生长因子受体治疗剂治疗的响应的预测物的cxcr1
WO2016088818A1 (ja) メチレンテトラヒドロ葉酸デヒドロゲナーゼ－２阻害薬に対する反応性を予測する方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180327